Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT06896916 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06896916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06896916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
August 7, 2025
Completion date
March 31, 2036
Enrollment
135 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma